Home › Trials › NCT02993029
Clinical trial Recruiting at 1 site Interventional Ages 40 and up

Treatment for knee osteoarthritis using 99Tc-MDP

Official title: 99Tc-MDP Versus Celecoxib Treatment in Patients With Knee Osteoarthritis

Run by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · NCT02993029 · Data updated 2026-11-12

This study is testing a new anti-inflammatory drug called 99Tc-MDP to see if it works better than celecoxib for people with knee osteoarthritis.

Quick facts

Study typeInterventional
Ages40 Years and up
SexAll
Enrollment40 (estimated)
SponsorXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedSeptember 1, 2017
Main results expectedDecember 30, 2027
Study endsDecember 30, 2027
Registry record updatedApril 28, 2026
Trial IDNCT02993029 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals with painful knee osteoarthritis and a specific uptake value on bone scans.

Probably not a fit

Patients who have undergone knee joint replacement or have inflammatory arthritis or joint infections will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of 99Tc-MDP, a patented anti-inflammatory drug, on patients suffering from knee osteoarthritis (OA) compared to the commonly used medication celecoxib. The study aims to address the increasing prevalence of knee OA, particularly among the aging population, and seeks to improve patient outcomes by potentially modifying the disease's progression. Participants will be evaluated based on specific criteria, including the severity of their OA as indicated by bone scans. The trial is conducted at Xinhua Hospital and the Tenth People's Hospital in Shanghai.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with knee osteoarthritis, potentially improving their quality of life.

How similar studies have gone: While 99Tc-MDP has been effective for rheumatoid arthritis, its application in knee osteoarthritis is novel and has not been extensively tested in previous studies.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Participants with painful osteoarthritis;
2. The standard uptake value (SUV) of OA related knee greater than 10 on 18F- sodium fluoride bone scan;
3. Participants voluntarily participate in the trial, and signed the informed consent.

Exclusion Criteria:

1. Knee joint replacement;
2. Inflammatory arthritis or joint infection of knee;
3. Nervous joint disease;
4. Fracture of joint;
5. Gout arthritis of the knee;
6. Traumatic arthritis.

Where it's running

  • Department of Nuclear Medicine, Tenth People's Hospital of Tongji University
    Shanghai, Shanghai Municipality, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Treatment Outcome 24Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 29
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.